Maitri Enterprises
- Market cap
- ₹ 15 Cr.
- P/E
- 17.1x
- P/B
- 3.02x
- 52-week range
- 22.1 – 48.4
- ROE
- 12%
- ROCE
- 15%
- Dividend yield
- 0%
- Debt / equity
- 0.92
- Sector
- Non - Ferrous Metals
- Industry
- Aluminium
- Listed on
- BSE
About
Maitri Enterprises Limited is an India-based company. The Company is primarily engaged on pharmaceutical business, construction and developmental activities in the real-estate market along with trading metal furniture and building materials. The Company is dedicated to expanding its product portfolio. Its segments include Pharmaceutical Goods, and Sale of service by way of works contract. The distribution network of the Company is in Ahmedabad region.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Aluminium: 18 companies →Maitri Enterprises against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.1 against a typical 20.8: cheaper than most peers (1st = cheapest).8th of 17
- Sales growth−25.4% against a typical +27.3% from a year earlier.13th of 13
- Share price, 3 months−20.5% against a typical −6.6%.14th of 16
- Size₹ 15.1 Cr. market value against a typical ₹ 214.7 Cr. (1st = largest).15th of 15
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 6 | 6 | 8 | 7 | 8 | 6 | 7 | 8 | 5 | 14 | 5 |
| Expenses | 3 | 6 | 6 | 7 | 6 | 6 | 6 | 8 | 7 | 4 | 13 | 5 |
| Operating Profit | 0 | 0 | −0 | 0 | 1 | 1 | −0 | −1 | 0 | 1 | 1 | −0 |
| OPM % | 2.5% | 4.4% | −2.9% | 3.5% | 13.1% | 16.3% | −5.1% | −10% | 4% | 19.1% | 5.8% | −5.4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | −1 | −0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | −1 | 0 | 1 | 0 | −1 | −1 | 0 | 1 | 1 | −0 |
| Tax % | 0% | 70.4% | −24.2% | 28.6% | 26.7% | 1,433.3% | −96.1% | −16.9% | −5.1% | 39.7% | 30.9% | 20.5% |
| Net Profit | 0 | 0 | −0 | 0 | 0 | −0 | −0 | −1 | 0 | 0 | 0 | −0 |
| EPS in Rs | 0 | 0.2 | −1.05 | 0.34 | 0.98 | −0.89 | −0.05 | −1.59 | 0.93 | 0.95 | 1.07 | −1.05 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 49%
- 3 Years
- 36%
- TTM
- 13%
- 10 Years
- —
- 5 Years
- 54%
- 3 Years
- —
- TTM
- 1,500%
- 10 Years
- 20%
- 5 Years
- 44%
- 3 Years
- 27%
- TTM
- —
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Maitri Enterprises | ₹ 32.59 | ₹ 15 Cr. | 17.1x | 3x | 12% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 26.2x | 2.5x | — | 10.6% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 67x | 13.2x | — | 21% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 23x | 4.2x | — | 28.6% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 46.5x | 1.3x | — | 13.2% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 33.3x | 5.3x | — | 15.5% |
Management
- Alpeshkumar Mohanbhai Patel
- Chief Financial Officer
- Rajshree Jain
- Chief Compliance Officer, Company Secretary
- Jaikishan Rameshlal Ambwani
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.